Skip to Content
Merck
  • Engineering Chirally Blind Protein Pseudocapsids into Antibacterial Persisters.

Engineering Chirally Blind Protein Pseudocapsids into Antibacterial Persisters.

ACS nano (2019-12-04)
Ibolya E Kepiro, Irene Marzuoli, Katharine Hammond, Xiaoliang Ba, Helen Lewis, Michael Shaw, Smita B Gunnoo, Emiliana De Santis, Urszula Łapińska, Stefano Pagliara, Mark A Holmes, Christian D Lorenz, Bart W Hoogenboom, Franca Fraternali, Maxim G Ryadnov
ABSTRACT

Antimicrobial resistance stimulates the search for antimicrobial forms that may be less subject to acquired resistance. Here we report a conceptual design of protein pseudocapsids exhibiting a broad spectrum of antimicrobial activities. Unlike conventional antibiotics, these agents are effective against phenotypic bacterial variants, while clearing "superbugs" in vivo without toxicity. The design adopts an icosahedral architecture that is polymorphic in size, but not in shape, and that is available in both l and d epimeric forms. Using a combination of nanoscale and single-cell imaging we demonstrate that such pseudocapsids inflict rapid and irreparable damage to bacterial cells. In phospholipid membranes they rapidly convert into nanopores, which remain confined to the binding positions of individual pseudocapsids. This mechanism ensures precisely delivered influxes of high antimicrobial doses, rendering the design a versatile platform for engineering structurally diverse and functionally persistent antimicrobial agents.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1,2-Didodecanoyl-sn-glycero-3-phosphocholine, ≥99%, synthetic
Sigma-Aldrich
Poly(dimethylsiloxane), viscosity 1.0 cSt (25 °C)
CellCrown inserts, 6 well plate inserts with 1.0 μm polycarbonate filter, sterile
Avanti
12:0 PC (DLPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine, chloroform
Avanti
12:0 PC (DLPC), Avanti Research - A Croda Brand
Avanti
12:0 PG, Avanti Research - A Croda Brand